{"id":"sipv-vaccine-dtap-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, redness, or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"},{"rate":null,"effect":"Drowsiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The sIPV (sequential inactivated poliovirus vaccine) component contains inactivated poliovirus types 1, 2, and 3 that trigger humoral and cellular immune responses. The DTaP component contains diphtheria and tetanus toxoids (inactivated bacterial toxins) and acellular pertussis antigens, which similarly induce protective antibody responses against these three bacterial pathogens. Together, the combination vaccine provides immunological protection against five vaccine-preventable diseases.","oneSentence":"This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against poliovirus (sIPV component) and diphtheria, tetanus, and pertussis toxins (DTaP component).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:08:19.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis (poliovirus types 1, 2, and 3)"},{"name":"Prevention of diphtheria"},{"name":"Prevention of tetanus"},{"name":"Prevention of pertussis (whooping cough)"}]},"trialDetails":[{"nctId":"NCT07354269","phase":"PHASE4","title":"Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-09-26","conditions":"Poliomyelitis","enrollment":180},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT04638985","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-13","conditions":"Vaccine","enrollment":600},{"nctId":"NCT04636827","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-11","conditions":"Vaccination","enrollment":600},{"nctId":"NCT04053010","phase":"PHASE4","title":"Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2019-08-10","conditions":"Vaccination","enrollment":702}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"sIPV vaccine /DTaP vaccine","genericName":"sIPV vaccine /DTaP vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against poliovirus (sIPV component) and diphtheria, tetanus, and pertussis toxins (DTaP component). Used for Prevention of poliomyelitis (poliovirus types 1, 2, and 3), Prevention of diphtheria, Prevention of tetanus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}